INTRODUCTION
The entry of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) into susceptible cells is mediated by binding of the viral spike (S) protein to its receptor molecule, angiotensin-converting enzyme 2 (ACE2). A pseudotyping system with vesicular stomatitis virus (VSV) particles [the VSV G* system, in which the VSV-G gene is replaced by the green fluorescent protein (GFP) gene] was reported to produce pseudotyped VSV incorporating envelope glycoproteins from RNA viruses. 1, 2 This system is useful for studies of viral envelope glycoproteins due to the ability to grow at high titers in a variety of cell lines. Infection of target cells with pseudotyped VSV can be detected readily as GFP-positive cells within 16 hours postinfection (hpi) because of the high level of GFP expression in the VSV G* system. 2 Thus, pseudotyping of SARS-CoV-S protein using the VSV G* system may have advantages for studying the function of SARS-CoV-S protein as well as for developing a rapid system for examining neutralizing antibodies specific for SARS-CoV infection. In this report, we describe a rapid detection system for SARS-CoV-S protein-bearing VSV pseudotype infection. The effects of ACE2-binding peptides on SARS-CoV-S-mediated infection were investigated using this system.
MATERIALS AND METHODS
Plasmids: cDNAs of the full-length or a truncated version of SARS-CoV-S protein lacking the C-terminal 19 amino acids were cloned into the mammalian expression vector, pKS336 3 yielding the plasmids, pKS-SARS-S and pKS-SARS-St19, respectively. The plasmid, pKS-SARS-St19rev, carried the same cDNA as pKS-SARS-St19 but in the reverse orientation in pKS336, and was used as a negative control for experiments regarding pseudotype production.
Preparation of VSV pseudotype: At 24 h after transfection of 293T cells with pKS-SARS-S, pKS-SARS-St19, or pKS-SARS-St19rev, the cells were infected with VSV G* in which the G gene was replaced by the GFP gene. 1 After 24 h, culture supernatants were collected and stored at -80°C until use. Vero E6 cells grown on 24-well glass slides were inoculated with pseudoviruses. Infection by pseudotype virus was detected by monitoring GFP expression under a fluorescence microscope, and the number of GFP-expressing cells was counted using ImageJ software (http://rsb.info.nih.gov/ij/). For inhibition assays, VSV pseudotypes were incubated with serially diluted inhibitors for 1 h at 37°C, and the mixtures were then inoculated onto Vero E6 cells.
Inhibitors: Angiotensin I, angiotensin II, and desArg 9 -bradykinin were purchased from Sigma. An ACE2 inhibitor, DX600, was purchased from Phoenix Pharmaceuticals.
RESULTS AND DISCUSSION

Production of SARS-CoV-S-Bearing VSV Pseudotype
To generate VSV pseudotyped with full-length SARS-CoV-S protein, the expression plasmid pKS-SARS-S was transfected into 293T cells, followed by infection with VSV G*. When the culture supernatants of the infected 293T cells were inoculated onto Vero E6 cells, a cell line commonly used for SARS-CoV propagation, only small numbers of GFP-expressing cells were observed (data not shown). These observations indicated that VSV pseudotype bearing the full-length SARS-CoV-S protein was not highly infectious. Next, we generated VSV pseudotyped with SARS-CoV-S protein in which the C-terminal 19 amino acids were truncated using the plasmid, pKS-SARS-St19. The plasmid, pKS-SARS-St19rev, was used as a negative control. 293T cells transfected with either pKS-SARS-St19 or pKS-SARS-St19rev were infected with VSV G*. After 24 h, the culture supernatants of infected cells were collected and inoculated onto Vero E6 cells. As shown in Figure 1 , the number of infectious units (IU) of pseudotyped VSV (5.0×10 5 /ml), referred to as VSV-SARS-St19, obtained from 293T cells transfected with pKS-SARS-St19 was significantly higher than that of the negative control. As partial deletion of the cytoplasmic domain of the SARS-CoV-S protein allowed efficient incorporation into VSV particles and led to pseudotype generation at high titer, the intact cytoplasmic domain of SARS-CoV-S protein may interrupt proper assembly of the pseudotype particles.
Time Course Analysis of GFP Expression in VSV Pseudotype-Infected Cells
Infection by retrovirus-based pseudotypes is usually measured at 48 hpi, while infection of VSV-based pseudotypes can be detected at 16 h. 2 Interestingly, GFP expression in Vero E6 cells was detected clearly at 7 h after inoculation with VSV-SARS-St19. Time course analysis of the number of GFP-positive cells indicated that it was possible to quantify VSV-SARS-St19 infection at 7 hpi (Fig. 1B) . Therefore, in subsequent analyses, we counted the number of GFP-positive cells infected with VSV-SARS-St19 at 7 hpi. , angiotensin II (AT2), or desArg 9 -bradykinin (BR) followed by inoculation onto Vero E6 cells. Infectivity of the pseudotypes was examined using the methods described in Figure 1 .
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Inhibition of VSV-SARS-St19 Infection
VSV-SARS-St19 infection of Vero E6 cells was neutralized by anti-SARS-CoV antibody (data not shown). Furthermore, a recombinant human ACE2 ectodomain protein, soluble ACE2, 4 strongly affected VSV-SARS-St19 infection but did not affect infection of VSV-G-bearing pseudotype (VSV G*-G; Fig. 2A ). These results indicated that VSV-SARS-St19 infection is mediated by SARS-CoV-S protein in an ACE2-dependent manner. We then investigated whether a known ACE2-specific peptide inhibitor can compete with ACE2-mediated pseudotype virus infection. As shown in Figure 2B , pretreatment of Vero E6 cells with DX600, which has been shown to inhibit ACE2 enzymatic activity, 5 inhibited VSV-SARS-St19 infection, while pretreatment with ACE2 peptide substrates, angiotensin I, angiotensin II, or desArg 9 -bradykinin, did not. Higher concentrations (>1.25 µM) of DX600 were required for 30-50% inhibition of VSV-SARS-St19 infection, indicating that this inhibition was weak (Fig. 2B) . Enzymatic activity is not required for ACE2 protein to act as a SARS-CoV receptor. 6 However, our results indicated that DX600 partially influenced the function of ACE2 as a SARS-CoV receptor. Further investigations, including inhibition studies with live SARS-CoV, are necessary to elucidate the efficacy of DX600. Our results suggested that ACE2-binding peptides can be used as specific inhibitors of SARS-CoV-S-mediated infection. Based on the results of neutralization experiments using anti-SARS-CoV antibody and soluble ACE2, we concluded that VSV-SARS-St19 infection of target cells is mediated by SARS-CoV-S protein. The assay system described here will be useful not only for developing a safe and rapid method to detect neutralizing antibodies to SARS-CoV but also for screening for inhibitors of SARS-CoV-S-mediated infection.
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